These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 23968703)

  • 1. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
    Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
    JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel.
    Bonello L; Mancini J; Pansieri M; Maillard L; Rossi P; Collet F; Jouve B; Wittenberg O; Laine M; Michelet P; Bessereau J; Lemesle G; Dignat-George F; Paganelli F; Camoin-Jau L
    J Thromb Haemost; 2012 Oct; 10(10):1999-2005. PubMed ID: 22863374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
    Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL
    Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
    El Ghannudi S; Ohlmann P; Meyer N; Wiesel ML; Radulescu B; Chauvin M; Bareiss P; Gachet C; Morel O
    JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity.
    Gaglia MA; Torguson R; Pokharel S; Pakala R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2013; 14(2):76-80. PubMed ID: 23375617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
    Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
    Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
    Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
    JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay.
    Abtan J; Silvain J; Kerneis M; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Collet JP; Montalescot G
    Thromb Haemost; 2013 Nov; 110(5):1055-64. PubMed ID: 23925438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Laine M; Panagides V; Frère C; Cuisset T; Gouarne C; Jouve B; Thuny F; Paganelli F; Alessi MC; Mancini J; Bonello L
    J Thromb Haemost; 2019 Dec; 17(12):2188-2195. PubMed ID: 31351022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
    Pankert M; Quilici J; Loundou AD; Verdier V; Lambert M; Deharo P; Bonnet G; Gaborit B; Morange PE; Valéro R; Dutour A; Bonnet JL; Alessi MC; Cuisset T
    Am J Cardiol; 2014 Jan; 113(1):54-9. PubMed ID: 24182762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
    Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
    Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
    Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
    Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
    Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry.
    Danese E; Fava C; Beltrame F; Tavella D; Calabria S; Benati M; Gelati M; Gottardo R; Tagliaro F; Guidi GC; Cattaneo M; Minuz P
    J Thromb Haemost; 2016 Feb; 14(2):282-93. PubMed ID: 26576037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes.
    Cuisset T; Quilici J; Loosveld M; Gaborit B; Grosdidier C; Fourcade L; Gil JM; Moro PJ; Morange PE; Bonnet JL; Alessi MC
    Am Heart J; 2012 Sep; 164(3):327-33. PubMed ID: 22980298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.